BACKGROUND: RAS-coupled MAPK and PI3K pathways play a fundamental role in thyroid tumorigenesis, and classical genetic alterations upregulating these pathways are well characterized. We hypothesized that gene abnormality of negative modulators of these signaling pathways might be an important alternative genetic background for thyroid cancer. METHODS: By examining gene expression patterns of negative modulators of RAS signaling, we attempted to identify potential tumor suppressor genes. We then analyzed the methylation and mutation patterns of the identified gene in 101 thyroid tumors and tested its functions in vitro and in vivo to establish the tumor suppressor role in thyroid cancer. RESULTS: Among 13 negative modulators of the RAS pathway screened, RASAL1, encoding a RAS GTPase-activating protein, was frequently hypermethylated in thyroid cancers, which was coupled to its silencing in thyroid cancer cells. We also, for the first time, identified the presence of RASAL1 mutations, with a prevalence of 4.88% (n = 2 of 41) in follicular thyroid cancer (FTC) and 16.67% (n = 5 of 30) in anaplastic thyroid cancer (ATC). RASAL1 displayed MAPK- and PI3K-suppressing and thyroid tumor-suppressing activities, which were all impaired by the mutations. Hypermethylation and mutations of RASAL1 were mutually exclusive and collectively found in zero of 20 benign thyroid tumors, 3.22% (n = 1 of 31) of papillary thyroid cancers, 31.70% (n = 13 of 41) of FTCs, and 33.33% (n = 10 of 30) of ATCs. A rate of 20.83% (n = 5 of 24) of tumors carrying RASAL1 mutation or methylation at high levels (>50%) vs 44.16% (n = 34 of 77) of tumors carrying no RASAL1 mutation or methylation at low levels (< 50%) harbored any of the classical mutations (two-sided P = .02, Fisher exact test) in RAS, BRAF, PTEN, and PIK3CA genes in the MAPK and PI3K pathways, revealing a largely mutually exclusive relationship. CONCLUSIONS: We identified RASAL1 as a major tumor suppressor gene that is frequently inactivated by hypermethylation and mutations, providing a new alternative genetic background for thyroid cancer, particularly FTC and ATC.
BACKGROUND: RAS-coupled MAPK and PI3K pathways play a fundamental role in thyroid tumorigenesis, and classical genetic alterations upregulating these pathways are well characterized. We hypothesized that gene abnormality of negative modulators of these signaling pathways might be an important alternative genetic background for thyroid cancer. METHODS: By examining gene expression patterns of negative modulators of RAS signaling, we attempted to identify potential tumor suppressor genes. We then analyzed the methylation and mutation patterns of the identified gene in 101 thyroid tumors and tested its functions in vitro and in vivo to establish the tumor suppressor role in thyroid cancer. RESULTS: Among 13 negative modulators of the RAS pathway screened, RASAL1, encoding a RAS GTPase-activating protein, was frequently hypermethylated in thyroid cancers, which was coupled to its silencing in thyroid cancer cells. We also, for the first time, identified the presence of RASAL1 mutations, with a prevalence of 4.88% (n = 2 of 41) in follicular thyroid cancer (FTC) and 16.67% (n = 5 of 30) in anaplastic thyroid cancer (ATC). RASAL1 displayed MAPK- and PI3K-suppressing and thyroid tumor-suppressing activities, which were all impaired by the mutations. Hypermethylation and mutations of RASAL1 were mutually exclusive and collectively found in zero of 20 benign thyroid tumors, 3.22% (n = 1 of 31) of papillary thyroid cancers, 31.70% (n = 13 of 41) of FTCs, and 33.33% (n = 10 of 30) of ATCs. A rate of 20.83% (n = 5 of 24) of tumors carrying RASAL1 mutation or methylation at high levels (>50%) vs 44.16% (n = 34 of 77) of tumors carrying no RASAL1 mutation or methylation at low levels (< 50%) harbored any of the classical mutations (two-sided P = .02, Fisher exact test) in RAS, BRAF, PTEN, and PIK3CA genes in the MAPK and PI3K pathways, revealing a largely mutually exclusive relationship. CONCLUSIONS: We identified RASAL1 as a major tumor suppressor gene that is frequently inactivated by hypermethylation and mutations, providing a new alternative genetic background for thyroid cancer, particularly FTC and ATC.
Authors: Cory M Johannessen; Elizabeth E Reczek; Marianne F James; Hilde Brems; Eric Legius; Karen Cichowski Journal: Proc Natl Acad Sci U S A Date: 2005-06-03 Impact factor: 11.205
Authors: Hongchuan Jin; Xian Wang; Jianming Ying; Ada H Y Wong; Yan Cui; Gopesh Srivastava; Zhong-Ying Shen; En-Min Li; Qian Zhang; Jie Jin; Sabine Kupzig; Anthony T C Chan; Peter J Cullen; Qian Tao Journal: Proc Natl Acad Sci U S A Date: 2007-07-18 Impact factor: 11.205
Authors: Huayang Liu; James A Dowdle; Safiya Khurshid; Nicholas J Sullivan; Nicholas Bertos; Komal Rambani; Markus Mair; Piotr Daniel; Esther Wheeler; Xing Tang; Kyle Toth; Michael Lause; Markus E Harrigan; Karl Eiring; Connor Sullivan; Matthew J Sullivan; Serena W Chang; Siddhant Srivastava; Joseph S Conway; Raleigh Kladney; Joseph McElroy; Sooin Bae; Yuanzhi Lu; Ali Tofigh; Sadiq M I Saleh; Soledad A Fernandez; Jeffrey D Parvin; Vincenzo Coppola; Erin R Macrae; Sarmila Majumder; Charles L Shapiro; Lisa D Yee; Bhuvaneswari Ramaswamy; Michael Hallett; Michael C Ostrowski; Morag Park; Helen M Chamberlin; Gustavo Leone Journal: Dev Cell Date: 2017-05-22 Impact factor: 12.270
Authors: Yanqiang Wang; Sandya Liyanarachchi; Katherine E Miller; Taina T Nieminen; Daniel F Comiskey; Wei Li; Pamela Brock; David E Symer; Keiko Akagi; Katherine E DeLap; Huiling He; Daniel C Koboldt; Albert de la Chapelle Journal: Thyroid Date: 2019-05-13 Impact factor: 6.568